Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls

(2012) Jörg Schilcher et al.   BONE

Bone strength and surrogate markers: The first, second, and third fiddle

(2012) Paul D Miller   JOURNAL OF BONE AND MINERAL RESEARCH

Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective

(2012) Steven Boonen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incidence of atypical nontraumatic diaphyseal fractures of the femur

(2012) Richard M Dell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

(2012) Sundeep Khosla et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bisphosphonates for Osteoporosis — Where Do We Go from Here?

(2012) Marcea Whitaker et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies

(2010) Stuart L. Silverman   CALCIFIED TISSUE INTERNATIONAL

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial

(2010) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

(2010) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

(2009) S.T. Harris et al.   BONE

Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study

(2009) G. Ioannidis et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Abstracts of Eighth International Symposium on Osteoporosis: Translating Research into Clinical Practice

(2009)   OSTEOPOROSIS INTERNATIONAL

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

(2008) Jacob A. Stakkestad et al.   CLINICAL RHEUMATOLOGY

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study

(2008) Steven Boonen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Severely Suppressed Bone Turnover and Atypical Skeletal Fragility

(2008) Maja Visekruna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

More on Atypical Fractures of the Femoral Diaphysis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate

(2008) Brett A. Lenart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

(2008) A. Cranney et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

(2007) Pierre D. Delmas et al.   BONE